# US 2008/0287650 A1 · High purity peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287650 A1
- Document ID: US20080287650A1
- Status: Published application
- Kind: A1
- Application number: 12/074,454
- Filed: 2008-03-03
- Published: 2008-11-20
- Earliest claimed: 2007-03-01
- Inventors: Avi Tovi; Chaim Eidelman; Shimon Shushan; Shai Elster; Alon Hagi; Alexander Ivchenko; Gabriel-Marcus Butilca; Gil Zaoui; Eleonora Alterman; Leah Bar-Oz
- Web page: https://patentgrep.com/patent/US20080287650A1

## CPC

- C07K 14/58: Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
- C07K 1/02: in solution {(C07K1/003, C07K1/006 take precedence)}
- C07K 1/04: on carriers {(C07K1/003, C07K1/006 take precedence)}
- C07K 1/20: Partition-, reverse-phase or hydrophobic interaction chromatography
- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- C07K 14/57509: {Corticotropin releasing factor [CRF] (Urotensin)}
- C07K 14/57563: {Vasoactive intestinal peptide [VIP]; Related peptides}
- C07K 14/57581: {Thymosin; Related peptides}
- C07K 14/60: Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- C07K 14/635: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- C07K 14/815: from leeches, e.g. hirudin, eglin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to methods for the preparation of highly purified peptides. The peptides are prepared in high optical purity of at least about 98.5%, and preferably at least about 99%. Specifically, Nesiritide (SEQ. ID NO. 1) having a purity of at least 99% as measured by HPLC and containing about 0.05% to about 0.5% [D-His]-Nesiritide (SEQ. ID NO. 1) as measured by chiral GC/MS.

## Claims

### Claim 1

A process for preparing a peptide of high purity comprising: (a) providing a fully protected peptide having at least one acid labile protecting group and at least one orthogonal protecting group; (b) deprotecting the acid labile protecting groups from the fully protected peptide with an acidic composition yielding a semi-protected peptide; (c) purifying the semi-protected peptide by HPLC; (d) deprotecting the orthogonal protecting groups from the semi-protected peptide with a deprotecting agent yielding a fully deprotected peptide; and (e) purifying the fully deprotected peptide by HPLC, wherein if the fully protected peptide contains two or more thiol-containing residues, then all the thiol-containing residues are protected by the acid labile protecting groups.

### Claim 2 (depends on 1)

The process of claim 1, wherein the peptide is linear.

### Claim 3 (depends on 1)

The process of claim 1, wherein the peptide is cyclic.

### Claim 4 (depends on 1)

The process of claim 1, wherein the fully protected peptide is prepared on a solid support or in solution.

### Claim 5 (depends on 1)

The process of claim 1, wherein the acid labile protecting group is t-butyl ester, trityl, t-butyloxycarbonyl, 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl, or t-butyl.

### Claim 6 (depends on 1)

The process of claim 1, wherein the orthogonal protecting group is 9-fluorenylmethyloxycarbonyl, benzyloxycarbonyl, benzyl, α,α-dimethyl-3,5-dimethoxybenzyloxylcarbonyl, 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl, 2,4-dinitrophenyl, benzyl ester, 9-fluorenymethyl ester, Nα-2-(4-Nitrophenylsulfonyl)ethoxycarbonyl, allyloxycarbonyl or acetamidomethyl.

### Claim 7 (depends on 1)

The process of claim 1, wherein the acidic composition comprises an acidic material and at least one scavenger reagent.

### Claim 8 (depends on 7)

The process of claim 7, wherein the acidic material is trifluoroacetic acid, hydrofluoric acid, trifluoromethanesulfonic acid or hydrobromic acid/acetic acid.

### Claim 9 (depends on 7)

The process of claim 7, wherein the scavenger reagents are triisopropylsilane, 1,2-ethanedithiol, water, phenol, m-cresol, thioanisole, dodecylmercaptane or dithioerythritol.

### Claim 10 (depends on 7)

The process of claim 7, wherein the acidic material is present in an amount of about 50% to about 99% by volume of the acidic composition, and the scavenger reagents are present in an amount of about 1% to about 50% by volume of the acidic composition.

### Claim 11 (depends on 1)

The process of claim 1, wherein the deprotecting agent is piperidine, 1,8-diazobicyclo[5.4.0]undec-7-ene, p-dimethylaminopyridine, triethylamine, hydrogen bromide/acetic acid, H2/Pd/C, hydrazine, hydrofluoric acid, or trifluoromethanesulfonic acid.

### Claim 12 (depends on 1)

The process of claim 1, wherein the process further comprises at least one step of neutralizing excess deprotecting agent, drying the fully deprotected peptide, purifying the fully deprotected peptide by counter-ion exchange, adding a histidine residue onto a carboxyl terminal of the fully protected peptide or cyclizing the fully deprotected peptide.

### Claim 13 (depends on 2)

The process of claim 2, wherein the linear peptide is Elcatonin (SEQ. ID NO. 5), Teriparatide (SEQ. ID NO. 4), Bivalirudin (SEQ. ID NO. 6), Exenatide (SEQ. ID NO. 2), Sermorelin (SEQ. ID NO. 7), Corticorelin (SEQ. ID NO. 8), Enfuvirtide (SEQ. ID NO. 3), Thymosin alpha 1 (SEQ. ID NO. 9), or Secretin (SEQ. ID NO. 10).

### Claim 14 (depends on 3)

The process of claim 3, wherein the cyclic peptide is Nesiritide (SEQ. ID NO. 1) or Pramlintide (SEQ. ID NO. 11).

### Claim 15 (depends on 13, 14)

The process of claims 13 or 14, wherein the peptide has a purity of at least 97.5% as measured by HPLC.

### Claim 16 (depends on 13, 14)

The process of claims 13 or 14, wherein the peptide has a purity of at least 98.5% as measured by HPLC.

### Claim 17 (depends on 13, 14)

The process of claims 13 or 14, wherein the peptide has a purity of at least 99% as measured by HPLC.

### Claim 18

A process for preparing Nesiritide (SEQ. ID NO. 1) comprising: (a) providing a fully protected peptide attached to a highly acid sensitive resin having the formula X-Ser(Y)-Pro-Lys(Y)-Met-Val-Gln(Y)-Gly-Ser(Y)-Gly-Cys(U)-Phe-Gly-Arg(Y)-Lys(Y)-Met-Asp(Y)-Arg(Y)-Ile-Ser(Y)-Ser(Y)-Ser(Y)-Ser(Y)-Gly-Leu-Gly-Cys(U)-Lys(Y)-Val-Leu-Arg(Y)-Arg(Y)-O-Resin (SEQ. ID NO. 1), wherein X is an acid labile or orthogonal protecting group, U is an acid labile or orthogonal protecting group on a cysteine residue, and Y is an acid labile protecting group; (b) reacting the fully protected peptide with a weak acidic composition to cleave the fully protected peptide from the resin, providing the fully protected peptide X-Ser(Y)-Pro-Lys(Y)-Met-Val-Gln(Y)-Gly-Ser(Y)-Gly-Cys(U)-Phe-Gly-Arg(Y)-Lys(Y)-Met-Asp(Y)-Arg(Y)-Ile-Ser(Y)-Ser(Y)-Ser(Y)-Ser(Y)-Gly-Leu-Gly-Cys(U)-Lys(Y)-Val-Leu-Arg(Y)-Arg(Y)-OH (SEQ. ID NO. 1) in solution; (c) coupling H-His(X)-O(Z) to produce X-Ser(Y)-Pro-Lys(Y)-Met-Val-Gln(Y)-Gly-Ser(Y)-Gly-Cys(U)-Phe-Gly-Arg(Y)-Lys(Y)-Met-Asp(Y)-Arg(Y)-Ile-Ser(Y)-Ser(Y)-Ser(Y)-Ser(Y)-Gly-Leu-Gly-Cys(U)-Lys(Y)-Val-Leu-Arg(Y)-Arg(Y)-His(X)-O(Z) (SEQ. ID NO. 1), wherein Z is a carboxy-terminal histidine protecting group which is either an orthogonal or acid-labile protecting group; (d) isolating the fully protected peptide by either evaporating the solvent or precipitating using a suitable co-solvent; (e) deprotecting the acid labile protecting groups in the fully protected peptide by treatment with an acidic composition to produce a semi-protected peptide, X-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His(X)-OZ (SEQ. ID NO. 1) or a non-protected linear peptide H-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His-OH (SEQ. ID NO. 1); (f) purifying the semi-protected peptide by preparative HPLC; (g) deprotecting the remaining orthogonal protecting groups from the semi-protected peptide to provide a fully deprotected peptide; (h) purifying the fully deprotected peptide by preparative HPLC; (i) cyclizing the fully deprotected peptide to provide a cyclic peptide; (j) purifying the cyclic peptide by preparative HPLC; (k) exchanging the counter ion of the cyclic peptide to citrate; and (1) drying the cyclic peptide to provide Nesiritide (SEQ. ID NO. 1) in solid powder.

### Claim 19 (depends on 18)

Nesiritide (SEQ. ID NO. 1) obtained according to the process of claim 18 containing about 0.05% to about 0.5% [D-His]-Nesiritide (SEQ. ID NO. 1) as determined by chiral GC/MS.

### Claim 20 (depends on 18)

The process of claim 18, wherein the highly acid sensitive resin is 2-chlorotrityl-chloride.

### Claim 21 (depends on 18)

The process of claim 18, wherein the orthogonal protecting group remained on the semi-protected cysteine residue can be deprotected from the peptide during the cyclization step using iodine.

### Claim 22

A peptide-resin conjugate of formula 1:
A-B-Resin
wherein A=X-Ser(Y)-Pro-Lys(Y)-Met-Val-Gln(Y)-Gly-Ser(Y)-Gly-Cys(U)-Phe-Gly-Arg(Y)-Lys(Y)-Met-Asp(Y)-Arg(Y)-Ile-Ser(Y)-Ser(Y)-Ser(Y)-Ser(Y)-Gly-Leu-Gly-Cys(U)-Lys(Y)-Val-Leu-Arg(Y)-Arg(Y)-O-, X is an orthogonal or acid labile protecting group, U is an orthogonal or acid labile protecting group on a cysteine residue, and Y is an acid labile protecting group; B is 2-chlorotrityl-chloride, and Resin is a solid matrix attached to the peptide.

### Claim 23 (depends on 22)

The peptide-resin conjugate of claim 22, wherein the protecting group (X) is 9-fluorenylmethyloxycarbonyl or t-butyloxycarbonyl and the protecting group (U) is acetamidomethyl or trityl.

### Claim 24 (depends on 23)

The peptide-resin conjugate of claim 23, wherein the protecting group (X) is t-butyloxycarbonyl and the protecting group (U) is trityl.

### Claim 25

Nesiritide (SEQ. ID NO. 1) containing about 0.05% to about 0.5% [D-His]-Nesiritide (SEQ. ID NO. 1) as determined by chiral GC/MS.

### Claim 26

Nesiritide (SEQ. ID NO. 1) containing about 0.05% to about 0.5% [D-His]-Nesiritide (SEQ. ID NO. 1) as determined by chiral GC/MS, made by a process comprising; providing X-Ser(Y)-Pro-Lys(Y)-Met-Val-Gln(Y)-Gly-Ser(Y)-Gly-Cys(U)-Phe-Gly-Arg(Y)-Lys(Y)-Met-Asp(Y)-Arg(Y)-Ile-Ser(Y)-Ser(Y)-Ser(Y)-Ser(Y)-Gly-Leu-Gly-Cys(U)-Lys(Y)-Val-Leu-Arg(Y)-Arg(Y)-OH (SEQ. ID NO. 1) attach to a resin; and coupling of H-His(X)-O(Z) to X-Ser(Y)-Pro-Lys(Y)-Met-Val-Gln(Y)-Gly-Ser(Y)-Gly-Cys(U)-Phe-Gly-Arg(Y)-Lys(Y)-Met-Asp(Y)-Arg(Y)-Ile-Ser(Y)-Ser(Y)-Ser(Y)-Ser(Y)-Gly-Leu-Gly-Cys(U)-Lys(Y)-Val-Leu-Arg(Y)-Arg(Y)-OH (SEQ. ID NO. 1) after cleavage of X-Ser(Y)-Pro-Lys(Y)-Met-Val-Gln(Y)-Gly-Ser(Y)-Gly-Cys(U)-Phe-Gly-Arg(Y)-Lys(Y)-Met-Asp(Y)-Arg(Y)-Ile-Ser(Y)-Ser(Y)-Ser(Y)-Ser(Y)-Gly-Leu-Gly-Cys(U)-Lys(Y)-Val-Leu-Arg(Y)-Arg(Y)-OH (SEQ. ID NO. 1) from the resin, wherein X is an orthogonal or acid labile protecting group, U is an orthogonal or acid labile protecting group on a cysteine residue, Y is an acid labile protecting group and Z is a carboxy-terminal histidine protecting group which is either an orthogonal or acid labile protecting group.

### Claim 27

Teriparatide (SEQ. ID NO. 4) having a purity of at least 98.5% as measured by HPLC.

### Claim 28

Bivalirudin (SEQ. ID NO. 6) containing not more than 0.5% [Asp9-Bivalirudin] (SEQ. ID NO. 6), not more than 0.5% [+Gly]-Bivalirudin (SEQ. ID NO. 6) and not more than 0.5% of any other impurity.

### Claim 29

Exenatide (SEQ. ID NO. 2) having a purity of at least 98.5% as measured by HPLC.

### Claim 30

Sermorelin (SEQ. ID NO. 7) having a purity of at least 98.5% as measured by HPLC.

### Claim 31

Corticorelin (SEQ. ID NO. 8) having a purity of at least 98.5% as measured by HPLC.

### Claim 32

Enfuvirtide (SEQ. ID NO. 3) having a purity of at least 98.5% as measured by HPLC.

### Claim 33

Thymosin alpha 1 (SEQ. ID NO. 9) having a purity of at least 98.5% as measured by HPLC.

### Claim 34

Pramlintide (SEQ. ID NO. 11) having a purity of at least 98.5% as measured by HPLC.
